Melek Ergin

2.0k total citations
89 papers, 1.5k citations indexed

About

Melek Ergin is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Melek Ergin has authored 89 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 27 papers in Pathology and Forensic Medicine and 27 papers in Oncology. Recurrent topics in Melek Ergin's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Viral-associated cancers and disorders (10 papers). Melek Ergin is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Viral-associated cancers and disorders (10 papers). Melek Ergin collaborates with scholars based in Türkiye, United States and Switzerland. Melek Ergin's co-authors include Semra Paydaş, Suzan Zorludemir, Serhan Alkan, Gülşah Şeydaoğlu, Şeyda Erdoğan, Sinan Yavuz, Hongyu Ni, Berksoy Şahin, Keith F. Izban and Qin Huang and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Periodontology and British Journal of Haematology.

In The Last Decade

Melek Ergin

87 papers receiving 1.4k citations

Peers

Melek Ergin

ONCOL

PFM

HEMAT

Batia Avni Israel

Katsuji Shinagawa Japan

I Philip France

Bernhard Meister Austria

Kazuma Ikeda Japan

Lalit Sehgal United States

Masakazu Nitta Japan

João L. Ascensão United States

Akihiko Yokohama Japan

Fumio Bessho Japan

Batia Avni Israel

Melek Ergin

419 ×0.8

449 ×1.0

ONCOL

243 ×0.7

PFM

399 ×1.2

HEMAT

146 ×0.6

Citations per year, relative to Melek Ergin Melek Ergin (= 1×) peers Batia Avni

Countries citing papers authored by Melek Ergin

Since Specialization

Citations

This map shows the geographic impact of Melek Ergin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melek Ergin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melek Ergin more than expected).

Fields of papers citing papers by Melek Ergin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melek Ergin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melek Ergin. The network helps show where Melek Ergin may publish in the future.

Co-authorship network of co-authors of Melek Ergin

This figure shows the co-authorship network connecting the top 25 collaborators of Melek Ergin. A scholar is included among the top collaborators of Melek Ergin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melek Ergin. Melek Ergin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Paydaş, Semra, et al.. (2023). Effects of enhancer of zeste homolog 2 and mucin 1 expressions on treatment response in breast cancer. Revista da Associação Médica Brasileira. 69(1). 153–158. 1 indexed citations

Rencüzoğulları, Ahmet, et al.. (2022). Modified techniques versus Hadfield’s procedure in patients with periductal mastitis. BMC Surgery. 22(1). 40–40. 2 indexed citations

Paydaş, Semra, Emine Kılıç Bağır, & Melek Ergin. (2018). Dynamic changes in PD-1 and PD-L1 expressions in cases with Hodgkin Lymphoma. 4(1). 1 indexed citations

Paydaş, Saime, Semra Paydaş, & Melek Ergin. (2015). Colchicine therapy in amyloidosis related with plasmacytic castleman disease presenting with nephrotic syndrome. Saudi Journal of Kidney Diseases and Transplantation. 26(5). 992–992. 4 indexed citations

Paydaş, Semra, et al.. (2015). Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Annals of Hematology. 94(9). 1545–1552. 71 indexed citations

Tuzlalı, Sıtkı, Ekrem Yavuz, Tülay Canda, et al.. (2014). In situ hybridization analysis of invasive breast carcinomas with immunohistochemically negative her-2 status (a national multicenter study). Turkish Journal of Pathology. 30(2). 87–87. 2 indexed citations

Duman, Berna Bozkurt, et al.. (2013). PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.. PubMed. 18(1). 44–50. 19 indexed citations

Paydaş, Saime, Semra Paydaş, Mustafa Balal, et al.. (2013). Late Onset Epstein Barr Virus Seropositive Posttransplant Lymphoproliferative Disorder in Two Renal Transplant Receivers. SHILAP Revista de lepidopterología. 30(3). 315–320. 1 indexed citations

Açıkalın, Arbil, Emine Kılıç Bağır, Şeyda Erdoğan, et al.. (2013). Perinatal autopsy evaluation of 2150 autopsies in the Çukurova region of turkey. Turkish Journal of Pathology. 30(3). 189–94. 6 indexed citations

10.

Paydaş, Semra, Gülşah Şeydaoğlu, Melek Ergin, Şeyda Erdoğan, & Sinan Yavuz. (2009). The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leukemia & lymphoma. 50(3). 366–373. 22 indexed citations

11.

Özçelik, Onur, M. Cenk Haytaç, Melek Ergin, Bülent Antmen, & Gülşah Şeydaoğlu. (2008). The immunohistochemical analysis of vascular endothelial growth factors A and C and microvessel density in gingival tissues of systemic sclerosis patients: their possible effects on gingival inflammation. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 105(4). 481–485. 20 indexed citations

12.

Bayazıt, Aysun Karabay, et al.. (2006). Renal amyloidosis in a child with sickle cell anemia. Pediatric Nephrology. 21(6). 877–879. 6 indexed citations

13.

Zander, Dani S., Jing Liu, R Barrios, et al.. (2005). Quality Assurance. Modern Pathology. 18. 322–325. 1 indexed citations

14.

Reyhan, Mehmet, et al.. (2005). Sonographic Diagnosis of a Tracheal Extramedullary Plasmacytoma. Journal of Ultrasound in Medicine. 24(7). 1031–1034. 11 indexed citations

15.

Soy, Mehmet, Melek Ergin, & Semra Paydaş. (2004). Lymphadenopathy in adult-onset Still?s disease mimicking peripheral T-cell lymphoma. Clinical Rheumatology. 23(1). 81–82. 7 indexed citations

16.

Kara, İsmail Oğuz, Melek Ergin, Berksoy Şahin, Ayşe Seza İnal, & Yeşim Taşova. (2004). Sinus Histiocytosis with Massive Lymphadenopathy (Rosai-Dorfman's Disease) Previously Misdiagnosed as Toxoplasma Lymphadenitis. Leukemia & lymphoma. 45(5). 1037–1041. 7 indexed citations

17.

Erdoğan, Şeref, Melek Ergin, & I Tuncer. (2003). Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.. PubMed. 50(5). 326–30. 3 indexed citations

18.

Paydaş, Semra, Melek Ergin, Fikri Başlamıslı, et al.. (2002). Bone marrow necrosis: Clinicopathologic analysis of 20 cases and review of the literature. American Journal of Hematology. 70(4). 300–305. 97 indexed citations

19.

Wrone-Smith, Tamara, Keith F. Izban, Melek Ergin, et al.. (2001). Transfection of caspase-3 in the caspase-3–deficient Hodgkin's disease cell line, KMH2, results in enhanced sensitivity to CD95-, TRAIL-, and ARA-C–induced apoptosis. Experimental Hematology. 29(5). 572–581. 13 indexed citations

20.

Izban, Keith F., et al.. (2000). Expression of the Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) 1 and 2 is a Characteristic Feature of Hodgkin and Reed-Sternberg Cells. Modern Pathology. 13(12). 1324–1331. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact